0001209191-22-008565.txt : 20220210
0001209191-22-008565.hdr.sgml : 20220210
20220210180736
ACCESSION NUMBER: 0001209191-22-008565
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20211118
FILED AS OF DATE: 20220210
DATE AS OF CHANGE: 20220210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Csimma Cristina
CENTRAL INDEX KEY: 0001501623
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33672
FILM NUMBER: 22615715
MAIL ADDRESS:
STREET 1: 14 CAMBRIDGE CENTER, BLDG 1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALISADE BIO, INC.
CENTRAL INDEX KEY: 0001357459
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 522007292
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5800 ARMADA DRIVE, SUITE 210
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: (858) 704-4900
MAIL ADDRESS:
STREET 1: 5800 ARMADA DRIVE, SUITE 210
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: Seneca Biopharma, Inc.
DATE OF NAME CHANGE: 20200127
FORMER COMPANY:
FORMER CONFORMED NAME: Neuralstem, Inc.
DATE OF NAME CHANGE: 20060324
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-18
0
0001357459
PALISADE BIO, INC.
PALI
0001501623
Csimma Cristina
C/O PALISADE BIO, INC.
5800 ARMADA DR., SUITE 210
CARLSBAD
CA
92008
1
0
0
0
Stock Option (right to buy)
2.32
2021-11-18
4
A
0
48340
0.00
A
2032-11-17
Common Stock
48340
48340
D
25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period.
/s/ Cristina Csimma
2022-02-10
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each THOMAS HALLAM, PH.D., JD FINLEY and RYKER WILLIE, signing individually, the
undersigned's true and lawful attorneys-in-fact and agents to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director or beneficial owner of more than 10% of a registered
class of securities of PALISADE BIO, INC. (the "Company"), Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID
(including any amendments thereto) and timely file such forms with the United
States Securities and Exchange Commission and any stock exchange or similar
authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by the Company
or Cooley LLP.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of February 10, 2022.
/s/ Cristina Csimma
Cristina Csimma, Pharm.D., MHP